Online inquiry

IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15975MR)

This product GTTS-WQ15975MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets Felcat IL31 gene. The antibody can be applied in Feline atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Felinized
RefSeq XM_011287838.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 105261056
UniProt ID A0A337S7E6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15975MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9857MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ15452MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ3071MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ12707MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ6609MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ9831MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ4905MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ1121MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-927
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW